Stephens resumed coverage of West Pharmaceutical (WST) with an Overweight rating and $250 price target The firm calls West “a high-quality, industry leading provider of containment solutions and services for injectable medications that is positioned to win within the defensive healthcare and life sciences industries.” The company is targeting 7%-9% organic growth along with 100 basis points of margin expansion annually as industry tailwinds – including biologics, GLP-1s, and stricter regulatory requirements – drive higher volumes and demand for high value components, the analyst tells investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Announces Departure of Senior Executive
- West Pharmaceutical price target lowered to $280 from $285 at BofA
- West Pharmaceutical can be ‘$370 stock’ in bull case, says Evercore ISI
- West Pharmaceutical initiated with an Outperform at Evercore ISI
- West Pharmaceutical Announces Leadership Transition